Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (21-30 of 266) with videos related to

Pageof 27
Sort By:
The Oncologist|February 3, 2011
The role of RANK-ligand inhibition in cancer: the story of denosumabDaniel Castellano, Juan Manuel Sepulveda, Ignacio García-Escobar, et al.
Cancer Treatment Reviews|July 14, 2020
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient careDaniel Castellano, Jose Pablo Maroto, Fawzi Benzaghou, et al.
Seminars in Oncology|February 7, 2003
Pemetrexed in bladder, head and neck, and cervical cancersLuis Paz-Ares, Eva Ciruelos, Rocío García-Carbonero, et al.
Metabolism: Clinical and Experimental|December 17, 2020
Human adipose tissue-derived stem cell paracrine networks vary according metabolic risk and after TNFα-induced death: An analysis at the single-cell levelWilfredo Oliva-Olivera, Daniel Castellano-Castillo, Ferdinand von Meyenn, et al.
The Oncologist|December 25, 2012
Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 studyDaniel Castellano, Emilio Bajetta, Ashok Panneerselvam, et al.
Oncotarget|February 2, 2022
Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learningIgnacio Durán, Daniel Castellano, Javier Puente, et al.
Expert Opinion on Pharmacotherapy|June 16, 2011
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patientsDaniel Castellano, José L González-Larriba, Luis M Antón-Aparicio, et al.
Therapeutic Advances in Medical Oncology|July 18, 2022
Cabozantinib for the treatment of solid tumors: a systematic reviewPablo Maroto, Camillo Porta, Jaume Capdevila, et al.
Biomedicines|October 23, 2021
Genome Profiling of H3k4me3 Histone Modification in Human Adipose Tissue during Obesity and Insulin ResistanceDaniel Castellano-Castillo, Bruno Ramos-Molina, Wilfredo Oliva-Olivera, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Cabozantinib combination therapy for the treatment of solid tumors: a systematic reviewDaniel Castellano, Andrea B Apolo, Camillo Porta, et al.
Pageof 27

Showing results (21-30 of 266) with videos related to

Sort By:
Pageof 27
The Oncologist|February 3, 2011
The role of RANK-ligand inhibition in cancer: the story of denosumabDaniel Castellano, Juan Manuel Sepulveda, Ignacio García-Escobar, et al.
Cancer Treatment Reviews|July 14, 2020
Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient careDaniel Castellano, Jose Pablo Maroto, Fawzi Benzaghou, et al.
Seminars in Oncology|February 7, 2003
Pemetrexed in bladder, head and neck, and cervical cancersLuis Paz-Ares, Eva Ciruelos, Rocío García-Carbonero, et al.
Metabolism: Clinical and Experimental|December 17, 2020
Human adipose tissue-derived stem cell paracrine networks vary according metabolic risk and after TNFα-induced death: An analysis at the single-cell levelWilfredo Oliva-Olivera, Daniel Castellano-Castillo, Ferdinand von Meyenn, et al.
The Oncologist|December 25, 2012
Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 studyDaniel Castellano, Emilio Bajetta, Ashok Panneerselvam, et al.
Oncotarget|February 2, 2022
Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learningIgnacio Durán, Daniel Castellano, Javier Puente, et al.
Expert Opinion on Pharmacotherapy|June 16, 2011
Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patientsDaniel Castellano, José L González-Larriba, Luis M Antón-Aparicio, et al.
Therapeutic Advances in Medical Oncology|July 18, 2022
Cabozantinib for the treatment of solid tumors: a systematic reviewPablo Maroto, Camillo Porta, Jaume Capdevila, et al.
Biomedicines|October 23, 2021
Genome Profiling of H3k4me3 Histone Modification in Human Adipose Tissue during Obesity and Insulin ResistanceDaniel Castellano-Castillo, Bruno Ramos-Molina, Wilfredo Oliva-Olivera, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Cabozantinib combination therapy for the treatment of solid tumors: a systematic reviewDaniel Castellano, Andrea B Apolo, Camillo Porta, et al.
Pageof 27